ASCO 2018 - Results from #40

Viewing 41-60 of 140 articles

ASCO 2018: A Phase II Trial of Enzalutamide, Docetaxel and Androgen Deprivation Therapy (ENZADA) in Patients with Metastatic Castrate Sensitive Prostate Cancer (mCSPC)

ASCO 2018: The Association of BRCA1 and BRCA2 Mutations on Prostate Cancer Risk, Frequency, and Mortality: Systematic Review and Meta-Analysis

ASCO 2018: Role of Surgery in Management of High-Risk Renal Cell Cancer

ASCO 2018: Systemic Therapy in Management of High-Risk Renal Cancer

ASCO 2018: Multicenter Randomized Phase 2 Trial of Paclitaxel, Ifosfamide, and Cisplatin Versus Bleomycin, Etoposide, and Cisplatin for First-line Treatment of Patients with Intermediate- or Poor-risk Germ Cell Tumors

ASCO 2018: The GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer in Washington State and Beyond

ASCO 2018: Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide

ASCO 2018: Subsequent Treatment after Abiraterone Acetate + Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-naïve Prostate Cancer: LATITUDE

ASCO 2018: Cabazitaxel in mCRPC: Real-life Use, Effectiveness, Safety, and Quality of Life in the FUJI Cohort

ASCO 2018: SPEAR-Bladder (Study Informing Treatment Pathway Decision in Bladder Cancer): First-Through Third-Line Time to Treatment Failure in the US

ASCO 2018: Sipuleucel-T OS and Clinical Outcomes by Baseline PSA Quartiles in Patients with mCRPC: PROCEED Registry

ASCO 2018: Bladder Cancer and Germ Cell Tumors

ASCO 2018: Immunotherapy in Prostate Cancer: The Path Forward

ASCO 2018: Optimal Integration of PARP Inhibitors for Prostate Cancer: Which Test, Which Patient, and Which Therapy?

ASCO 2018: Nonimmunotherapy Strategies in Advanced Bladder Cancer

ASCO 2018: Radiopharmaceuticals: Emitting the Right Signals in Prostate Cancer

ASCO 2018: Science of Oncology Award Lecture: Preventing HPV-Associated Cancers by Vaccination

ASCO 2018: Optimizing Systemic Therapy in Advanced Renal Cell Carcinoma

ASCO 2018: Patient-reported Outcomes in IMmotion151: Atezolizumab + Bevacizumab vs Sunitinib in Treatment Naive mRCC

ASCO 2018: Updated Phase 1 Data Announced for Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy

1
2
3
4
5
6
7